Circulation. 2002;105:1883-1886
Published online before print April 1, 2002, doi: 10.1161/01.CIR.0000016042.69606.61
Published online before print April 1, 2002, doi: 10.1161/01.CIR.0000016042.69606.61
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1883.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis
Immediate and Long-Term Clinical and Angiographic Outcome
From Catheterization Laboratories, Ospedale San Raffaele, and Emo Centro Cuore Columbus, Milan, Italy.
Correspondence to Antonio Colombo, MD, EMO Centro Cuore Columbus Hospital, Via M. Buonarroti 48, 20145, Milan, Italy. E-mail columbus{at}micronet.it
Background— It has been shown that antiproliferative drugs such as paclitaxel lower the amount of intimal hyperplasia after stent implantation. We report the first clinical experience of 7-hexanoyltaxol (QP2)–eluting polymer stent system (QuaDS) implantation for in-stent restenosis.
Methods and Results— Fifteen consecutive patients with elective indication to percutaneous coronary intervention for in-stent restenosis were treated with the QuaDS-QP2 stent implantation. The QuaDS-QP2 stent was successfully implanted in all but 2 target lesions. In one lesion, the restenotic segment could not be completely covered by the stent, and in another lesion, a bare metal stent was implanted distally to the QuaDS-QP2 stent. One patient suffered from postprocedural non–Q-wave myocardial infarction (NQWMI). No other adverse events were observed during hospital stay. Six- and 12-month angiographic and clinical follow-up was scheduled for all patients. At 6 months, 3 patients had target lesion revascularization (20%). Two patients had restenosis (13.3%); one experienced restenosis in a gap between 2 drug-eluting stents, and the other had stent occlusion leading to NQWMI. Minimal intimal hyperplasia was observed in all the segments covered by drug-eluting stents (late loss=0.47±1.01 mm with a loss index=0.17±0.39). At 12 months, 1 patient suffered from NQWMI, and 8 of 13 patients (61.5%) had angiographic restenosis (late loss=1.36±0.94 mm with a loss index=0.62±0.44).
Conclusion— This first experience with QuaDS-QP2 stent implantation for in-stent restenosis revealed minimal intimal hyperplasia at the 6-month follow-up. However, the antiproliferative effect was not maintained at the 12-month follow-up, resulting in delayed occurrence of angiographic restenosis.
Key Words: restenosis • stents • angiography
This article has been cited by other articles:
 |
|
 |
|
  W. Yang, J. Ge, H. Liu, K. Zhao, X. Liu, X. Qu, W. Li, Y. Huang, A. Sun, and Y. Zou Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model Cardiovasc Res, December 1, 2006; 72(3): 483 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Roiron, P Sanchez, A Bouzamondo, P Lechat, and G Montalescot Drug eluting stents: an updated meta-analysis of randomised controlled trials Heart, May 1, 2006; 92(5): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, M. R. Clark, B. M. Cohen, S. G. Ellis, P. Coleman, C. Hill, C. Shi, et al. Two-Year Outcomes After Sirolimus-Eluting Stent Implantation: Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1350 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Raja Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction. Ann. Thorac. Surg., March 1, 2006; 81(3): 1162 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, A. K. Jacobs, M. J. Kern, S. B. King III, D. A. Morrison, W. W. O'Neill, H. V. Schaff, P. L. Whitlow, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) J. Am. Coll. Cardiol., January 3, 2006; 47(1): 216 - 235. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, A. K. Jacobs, M. J. Kern, S. B. King III, D. A. Morrison, W. W. O'Neill, H. V. Schaff, P. L. Whitlow, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) Circulation, January 3, 2006; 113(1): 156 - 175. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wessely, A. Kastrati, and A. Schomig Late Restenosis in Patients Receiving a Polymer-Coated Sirolimus-Eluting Stent Ann Intern Med, September 6, 2005; 143(5): 392 - 394. [Full Text] [PDF]
|
|
|
|
|
|
A. V. Finn, F. D. Kolodgie, J. Harnek, L.J. Guerrero, E. Acampado, K. Tefera, K. Skorija, D. K. Weber, H. K. Gold, and R. Virmani Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents Circulation, July 12, 2005; 112(2): 270 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Shin, H.-Y. Song, C. G. Choi, S. H. Yuk, J.-S. Kim, Y. M. Kim, C. J. Yoon, T.-H. Kim, J.-Y. Suh, and X. He Tissue Hyperplasia: Influence of a Paclitaxel-eluting Covered Stent--Preliminary Study in a Canine Urethral Model Radiology, February 1, 2005; 234(2): 438 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Murphy, A. J. Bryan, and G. D. Angelini Hybrid Coronary Revascularization in the Era of Drug-Eluting Stents Ann. Thorac. Surg., November 1, 2004; 78(5): 1861 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Schwartz, N. A. Chronos, and R. Virmani Preclinical restenosis models and drug-eluting stents: Still important, still much to learn J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waksman, A. E. Ajani, A. D. Pichard, R. Torguson, E. Pinnow, D. Canos, L. F. Satler, K. M. Kent, P. Kuchulakanti, C. Pappas, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Iijima, Y Ikari, T Tsunoda, M Nakamura, K Hara, and T Yamaguchi Impact of intima re-intrusion and expansion within 100 minutes on late lumen loss in percutaneous coronary intervention for diffuse in-stent restenosis Heart, September 1, 2004; 90(9): 1071 - 1072. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vogt, A. Stein, G. Rettemeier, N. Krott, R. Hoffmann, J. v. Dahl, A.-K. Bosserhoff, W. Michaeli, P. Hanrath, C. Weber, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent Eur. Heart J., August 1, 2004; 25(15): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Walter, M. Cejna, L. Diaz-Sandoval, S. Willis, L. Kirkwood, P. W. Stratford, A. B. Tietz, R. Kirchmair, M. Silver, C. Curry, et al. Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents: An Alternative Strategy for Inhibition of Restenosis Circulation, July 6, 2004; 110(1): 36 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W Radke, S. Kobella, A. Kaiser, A. Franke, D. Schubert, E. Grube, P. Hanrath, and R. Hoffmann Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary {beta}-radiation therapy Eur. Heart J., June 1, 2004; 25(11): 920 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wessely, M. Paschalidis, S. Wagenpfeil, F. Wegener, F.-J. Neumann, and W. Theiss A comprehensive approach to visual and functional assessment of experimental vascular lesions in vivo Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2461 - H2467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr How Many Grails Do We Need? Circulation, May 11, 2004; 109(18): 2158 - 2159. [Full Text] [PDF]
|
|
|
|
 |
|
 P. H Chong and J. W. Cheng Early Experiences and Clinical Implications of Restenosis and Drug-Eluting Stents: Part 2 Ann. Pharmacother., May 1, 2004; 38(5): 845 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Curcio, D. Torella, G. Cuda, C. Coppola, M. C. Faniello, F. Achille, V. G. Russo, M. Chiariello, and C. Indolfi Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H902 - H908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr, M. B. Leon, J. W. Moses, J. J. Popma, D. Cutlip, P. J. Fitzgerald, C. Brown, T. Fischell, S. C. Wong, M. Midei, et al. Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis Circulation, February 10, 2004; 109(5): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Matsumoto, T. Uwatoku, K. Oi, K. Abe, T. Hattori, K. Morishige, Y. Eto, Y. Fukumoto, K.-i. Nakamura, Y. Shibata, et al. Long-Term Inhibition of Rho-Kinase Suppresses Neointimal Formation After Stent Implantation in Porcine Coronary Arteries: Involvement of Multiple Mechanisms Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 181 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Bhatia, R Bhatia, and M Dhindsa Drug-eluting stents: new era and new concerns Postgrad. Med. J., January 1, 2004; 80(939): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waksman, R. Lew, A. E. Ajani, A. D. Pichard, L. F. Satler, K. M. Kent, R. Chan, R. L. White, W. O. Suddath, E. Pinnow, et al. Repeat Intracoronary Radiation for Recurrent In-Stent Restenosis in Patients Who Failed Intracoronary Radiation Circulation, August 12, 2003; 108(6): 654 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Pearce and J. F. McKinsey Current Status of Intravascular Stents as Delivery Devices to Prevent Restenosis Vascular and Endovascular Surgery, July 1, 2003; 37(4): 231 - 237. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Lemos, P. W. Serruys, and J. E. Sousa Drug-Eluting Stents: Cost Versus Clinical Benefit Circulation, June 24, 2003; 107(24): 3003 - 3007. [Full Text] [PDF]
|
|
|
|
|
|
D. W. Losordo, J. M. Isner, and L. J. Diaz-Sandoval Endothelial Recovery: The Next Target in Restenosis Prevention Circulation, June 3, 2003; 107(21): 2635 - 2637. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, P. W. Serruys, and M. A. Costa New Frontiers in Cardiology: Drug-Eluting Stents: Part II Circulation, May 13, 2003; 107(18): 2383 - 2389. [Full Text] [PDF]
|
|
|
|
|
|
A. Finkelstein, D. McClean, S. Kar, K. Takizawa, K. Varghese, N. Baek, K. Park, M. C. Fishbein, R. Makkar, F. Litvack, et al. Local Drug Delivery via a Coronary Stent With Programmable Release Pharmacokinetics Circulation, February 11, 2003; 107(5): 777 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Virmani, F D Kolodgie, A Farb, and A Lafont Drug eluting stents: are human and animal studies comparable? Heart, February 1, 2003; 89(2): 133 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R Bennett IN-STENT STENOSIS: PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS Heart, February 1, 2003; 89(2): 218 - 224. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, M. A. Costa, A. G.M.R. Sousa, A. C. Abizaid, A. C. Seixas, A. S. Abizaid, F. Feres, L. A. Mattos, R. Falotico, J. Jaeger, et al. Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries Circulation, January 28, 2003; 107(3): 381 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, M. A. Costa, A. Abizaid, A. G.M.R. Sousa, F. Feres, L. A. Mattos, M. Centemero, G. Maldonado, A. S. Abizaid, I. Pinto, et al. Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study Circulation, January 7, 2003; 107(1): 24 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Grube, S. Silber, K. E. Hauptmann, R. Mueller, L. Buellesfeld, U. Gerckens, and M. E. Russell TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions Circulation, January 7, 2003; 107(1): 38 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Indolfi, D. Torella, C. Coppola, A. Curcio, F. Rodriguez, A. Bilancio, A. Leccia, O. Arcucci, M. Falco, D. Leosco, et al. Physical Training Increases eNOS Vascular Expression and Activity and Reduces Restenosis After Balloon Angioplasty or Arterial Stenting in Rats Circ. Res., December 13, 2002; 91(12): 1190 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part II Circulation, November 26, 2002; 106(22): 2859 - 2866. [Full Text] [PDF]
|
|
|
|
|
|
R. Virmani, F. Liistro, G. Stankovic, C. Di Mario, M. Montorfano, A. Farb, F. D. Kolodgie, and A. Colombo Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate-Eluting Polymer Stent System in Humans Circulation, November 19, 2002; 106(21): 2649 - 2651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Farb, M. John, E. Acampado, F. D. Kolodgie, M. F. Prescott, and R. Virmani Oral Everolimus Inhibits In-Stent Neointimal Growth Circulation, October 29, 2002; 106(18): 2379 - 2384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Delayed Restenosis After Use of a Paclitaxel-Eluting Stent Journal Watch Cardiology, June 21, 2002; 2002(621): 2 - 2. [Full Text]
|
|
|
|
 |
|
 G. Mozes and P. Gloviczki Adjuvant Therapy in Lower Extremity Revascularization: Prevention of Early and Intermediate Failures Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 2002; 15(2): 161 - 180. [Abstract] [PDF]
|
|